{
    "guideline": {
        "id": "PA166265141",
        "name": "Annotation of DPWG Guideline for allopurinol and HLA-B",
        "source": "DPWG",
        "version": 7,
        "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166265141",
        "relatedChemicals": [
            {
                "id": "PA448320",
                "name": "allopurinol",
                "symbol": null
            }
        ],
        "relatedGenes": [
            {
                "id": "PA35056",
                "name": "major histocompatibility complex, class I, B",
                "symbol": "HLA-B"
            }
        ],
        "recommendation": true
    },
    "recommendations": [
        {
            "id": "PA166299109",
            "name": "Recommendation PA166299109",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA448320",
                    "name": "allopurinol",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061472,
                "html": "<ul>\n<li>\n<p>Choose an alternative, such as febuxostat</p>\n</li>\n<li>\n<p>Another option is to induce allopurinol tolerance first: To induce allopurinol tolerance, the allopurinol dose is increased every 3 days until a dose of 100 mg/day has been achieved on Day 28. The consecutive daily doses in the\ninduction protocol are 50 \u00b5g, 100 \u00b5g, 200 \u00b5g, 500 \u00b5g, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg and 100 mg.</p>\n</li>\n</ul>\n"
            },
            "implications": [
                "A strongly increased risk of developing the life-threatening cutaneous side effects Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and DRESS is present in\npatients with this genetic variation. The risk of an allopurinol-induced life-threatening cutaneous side effect (mortality 11%) in these patients is 1.6-2.0% for the entire group\nand 8-18% for the group with chronic renal insufficiency."
            ],
            "lookupKey": {
                "HLA-B": "*58:01 positive"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        }
    ],
    "citations": [
        {
            "pmid": "36056234",
            "title": "Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and Allopurinol, and MTHFR, folic acid and methotrexate.",
            "authors": [
                "van der Pol Karel H",
                "Nijenhuis Marga",
                "Soree Bianca",
                "de Boer-Veger Nienke J",
                "Buunk Anne Marie",
                "Guchelaar Henk-Jan",
                "Risselada Arne",
                "van Schaik Ron H N",
                "Swen Jesse J",
                "Touw Daan",
                "van der Weide Jan",
                "van Westrhenen Roos",
                "Deneer Vera H M",
                "Houwink Elisa J F",
                "Rongen Gerard A"
            ],
            "journal": "European journal of human genetics : EJHG",
            "year": 2024
        }
    ],
    "version": "2024-03-25-16-13"
}